Literature DB >> 17253506

Combined oral contraceptive pills for treatment of acne.

A O Arowojolu1, M F Gallo, L M Lopez, D A Grimes, S E Garner.   

Abstract

BACKGROUND: Acne is a common skin disorder among women. Although no uniform approach to the management of acne exists, combination oral contraceptives (COCs), which contain an estrogen and a progestin, often are prescribed for women.
OBJECTIVES: To determine the effectiveness of combined oral contraceptives (COCs) for the treatment of facial acne compared to placebo or other active therapies. SEARCH STRATEGY: We searched the computerized databases of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, POPLINE, Biological Abstracts and LILACS for randomized controlled trials of COCs and acne. We wrote to authors of identified trials to seek any unpublished or published trials that we might have missed. SELECTION CRITERIA: All randomized controlled trials reported in any language that compared the effectiveness of a COC containing an estrogen and a progestin to placebo or another active therapy for acne in women were eligible. DATA COLLECTION AND ANALYSIS: We extracted data on total and specific (i.e., open or closed comedones, papules, pustules and nodules) facial lesion counts; acne severity grades; global assessments by the clinician or the participant and discontinuation due to adverse events. Data were entered and analyzed in RevMan. MAIN
RESULTS: The search yielded 23 trials: 5 placebo-controlled trials made 3 different comparisons, 17 trials made 13 comparisons between 2 different COC regimens, and 1 additional trial compared a COC to an antibiotic. COCs reduced acne lesion counts, severity grades and self-assessed acne compared to placebo. Differences in the comparative effectiveness of COCs containing varying progestin types and dosages, though, were less clear. COCs that contained chlormadinone acetate or cyproterone acetate improved acne better than levonorgestrel, although this apparent advantage was based on limited data. A COC with cyproterone acetate might result in better acne outcomes than one with desogestrel; however, the three studies comparing these COCs produced conflicting results. Likewise, levonorgestrel showed a slight improvement over desogestrel in acne outcomes in one trial, but a second trial found no difference between the COCs. AUTHORS'
CONCLUSIONS: The three COCs evaluated in placebo-controlled trials are effective in reducing inflammatory and non-inflammatory facial acne lesions. Few differences were found between COC types in their effectiveness for treating acne. How COCs compare to alternative acne treatments is unknown since limited data were available regarding this question.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253506     DOI: 10.1002/14651858.CD004425.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

1.  Taking the stress out of acne management.

Authors:  Tessa Laubscher; Loren Regier; Margaret Jin; Brent Jensen
Journal:  Can Fam Physician       Date:  2009-03       Impact factor: 3.275

2.  Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills.

Authors:  Abbey B Berenson; Susan D Odom; Carmen Radecki Breitkopf; Mahbubur Rahman
Journal:  Am J Obstet Gynecol       Date:  2008-07-03       Impact factor: 8.661

3.  Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.

Authors:  Lianne Parkin; Katrina Sharples; Rohini K Hernandez; Susan S Jick
Journal:  BMJ       Date:  2011-04-21

4.  Management strategies for acne vulgaris.

Authors:  Kristen M Whitney; Chérie M Ditre
Journal:  Clin Cosmet Investig Dermatol       Date:  2011-04-26

5.  Cervical spinal cord infarction associated with the use of oral contraceptives for the treatment of acne in a healthy young woman.

Authors:  F C Meng; J T Lee; G S Peng; Y F Sung
Journal:  J Postgrad Med       Date:  2015 Jan-Mar       Impact factor: 1.476

6.  The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.

Authors:  A van Hylckama Vlieg; F M Helmerhorst; J P Vandenbroucke; C J M Doggen; F R Rosendaal
Journal:  BMJ       Date:  2009-08-13

7.  A chewable low-dose oral contraceptive: a new birth control option?

Authors:  Edith Weisberg
Journal:  Patient Prefer Adherence       Date:  2012-04-24       Impact factor: 2.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.